{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:36Z","timestamp":1793295876560,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006528","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T00:00:00Z","timestamp":1323216000000}}],"reference-count":199,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006528.pub2","type":"journal-article","created":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T16:13:56Z","timestamp":1323101636000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Mirtazapine versus other antidepressive agents for depression"],"prefix":"10.1002","volume":"2011","author":[{"given":"Norio","family":"Watanabe","sequence":"first","affiliation":[{"name":"Nagoya City University Graduate School of Medical Sciences; Department of Psychiatry & Cognitive-Behavioral Medicine; Kawasumi 1 Mizuho-cho, Mizuho-ku Nagoya Aichi Japan 467-8601"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro M","family":"Omori","sequence":"additional","affiliation":[{"name":"Toyokawa City Hospital; Department of Psychiatry; Koumei 1-19 Toyokawa Aichi Japan 442-8561"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Keio University School of Medicine; Department of Psychiatry; Shinanomachi 35, Shinjuku-ku Tokyo Japan 160-8582"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology; Policlinico \"G.B.Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology; Policlinico \"G.B.Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Churchill","sequence":"additional","affiliation":[{"name":"University of Bristol; Academic Unit of Psychiatry, School of Social and Community Medicine; Oakfield Hourse Oakfield Grove Bristol UK BS8 2BN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine \/ School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 601-8501"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,7]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2710.2004.00585.x","article-title":"Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial","volume":"30","author":"Amini","year":"2005","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0002|cit2","unstructured":"Baker R Schutte AJ NR326 More rapid onset of sleep-improving effects with mirtazapine FDT versus sertraline 158th Annual Meeting of the American Psychiatric Association ; 2005 May 21-26 Atlanta, GA 2005"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"358-64 [Erratum","DOI":"10.1097\/01.jcp.0000085408.08426.05","article-title":"Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study","volume":"23","author":"Behnke","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD006528.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4088\/JCP.v61n0911","article-title":"Mirtazapine compared with paroxetine in major depression","volume":"61","author":"Benkert","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.jcp.0000194622.99986.d6","article-title":"Mirtazapine orally disintegrating tablets versus venlafaxine extended release","volume":"26","author":"Benkert","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD006528.pub2-BIB0006|cit6","first-page":"519","article-title":"A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression","volume":"56","author":"Bremner","year":"1995","journal-title":"Journal of Clinical Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD006528.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.4088\/JCP.v69n1205","article-title":"The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients","volume":"69","author":"Brunnauer","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006528.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1016\/S0924-977X(00)80213-8","article-title":"Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depression","volume":"10","author":"Debonnel","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD006528.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1176\/ajp.2006.163.7.1161","article-title":"A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report","volume":"163","author":"Fava","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00004714-200108000-00010","article-title":"Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features","volume":"21","author":"Guelfi","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hup.470100807","article-title":"Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients","volume":"10 Suppl","author":"Halikas","year":"1995","journal-title":"Human Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD006528.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4088\/JCP.v64n0810","article-title":"A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients","volume":"64","author":"Hong","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0447.1996.tb10629.x","article-title":"A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients","volume":"93","author":"Hoyberg","year":"1996","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Agren H Skarstein J Behke K Schutte A-J Leinonen E Efficacy and tolerability of mirtazapine versus citalopram in major depression: a double-blind, randomized study 152nd Annual Meeting of the American Psychiatric Association Washington DC, USA 1999 NR476","DOI":"10.1016\/S0924-977X(99)80170-9"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00004850-199911000-00002","article-title":"Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder","volume":"14","author":"Leinonen","year":"1999","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0924-977X(95)80002-J","article-title":"A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression","volume":"5","author":"Marttila","year":"1995","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/026988119601000310","article-title":"A multicentre, double-blind, amitriptyline-controIled study of mirtazapine in patients with major depression","volume":"10","author":"Mullin","year":"1996","journal-title":"Journal of Psychopharmacology"},{"issue":"1 Pt B","key":"10.1002\/14651858.CD006528.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00002826-199202001-00349","article-title":"Double-blind, multicentre comparison of remergon and amitriptyline in elderly depressed patients","volume":"15","author":"Roland","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"suppl 2","key":"10.1002\/14651858.CD006528.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1002\/hup.470100808","article-title":"Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis","volume":"10","author":"Zivkov","year":"1995","journal-title":"Human Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/hup.470100403","article-title":"A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770","volume":"10","author":"Richou","year":"1995","journal-title":"Human Psychopharmacology"},{"issue":"suppl 1 pt B","key":"10.1002\/14651858.CD006528.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002826-199202001-00456","article-title":"Remergon efficacy in major depressive episode: A randomized, double-blind, clomipramine-controlled study in 174 French hospitalized patients","volume":"15","author":"Ruimy","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0026|cit22","unstructured":"Murphy GM Pharmacogenetics of mirtazapine and paroxetine in the treatment of geriatric major depression 39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14 San Juan; Puerto Rico 2000 235"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0024|cit23","unstructured":"Murphy GM Jr Pharmacokinetic and pharmacodynamic genetic predictors of antidepressant tolerability and efficacy 45th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2005 June 6 - 9 Boca Raton, FL 2005 50"},{"issue":"11","key":"10.1002\/14651858.CD006528.pub2-BIB0022|cit24","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/archpsyc.61.11.1163","article-title":"Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression","volume":"61","author":"Murphy","year":"2004","journal-title":"Archives of General Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD006528.pub2-BIB0023|cit25","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1176\/appi.ajp.160.10.1830","article-title":"Pharmacogenetics of antidepressant medication intolerance","volume":"160","author":"Murphy","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006528.pub2-BIB0025|cit26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0006-3223(03)00174-4","article-title":"The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients","volume":"54","author":"Murphy","year":"2003","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0028|cit27","unstructured":"O'Hara R Schatzberg AF Murphy GM The impact on cognition of pharmacological treatment for late-life depression 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23 Philadelphia, PA 2002 No. 15B"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0027|cit28","unstructured":"O\u2019Hara R Hollander SB Lapp W Boyle L Rodrigues H Kraemer HC ApoE4 Allele influences antidepressants\u2019 cognitive effects in the elderly 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6 New York, NY 2004 NR876"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ajmg.b.31019","article-title":"FKBP5 polymorphisms and antidepressant response in geriatric depression","volume":"153B","author":"Sarginson","year":"2010","journal-title":"American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: the Official Publication of the International Society of Psychiatric Genetics"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0030|cit30","unstructured":"Schatzberg AF Kremer C Rodrigues H Mirtazapine and paroxetine in elderly depressed patients 52nd Institute on Psychiatric Services; 2000 October 25-29th Philadelphia, PA 2000"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0031|cit31","unstructured":"Schatzberg AF Kremer C Rodrigues H Mirtazapine versus paroxetine in elderly depressed patients 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 23rd-26th February San Francisco, Ca, USA 2001"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0032|cit32","unstructured":"Schatzberg AF Kremer C Rodrigues H Mirtazapine versus paroxetine in elderly depressed patients 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10 Orleans LA 2001 NR478"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0034|cit33","unstructured":"Schatzberg AF Kremer C Rodrigues HE Mirtazapine versus paroxetine in elderly depressed patients 39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14 San Juan; Puerto Rico 2000 97"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0033|cit34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00019442-200209000-00007","article-title":"Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients","volume":"10","author":"Schatzberg","year":"2002","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"suppl 1","key":"10.1002\/14651858.CD006528.pub2-BIB0035|cit35","first-page":"140","article-title":"First, randomized, double-blind comparison of mirtazapine (15-45 mg) and fluvoxamine (50-150 mg) in the treatment of depression","volume":"5","author":"Schoemaker","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0036|cit36","unstructured":"Schoemaker JH The Mirtazapine Bridging Study Group Double-blind comparison of mirtazapine versus fluvoxamine in patients with major depressive disorder (DSM-IV) In preparation"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00213-006-0382-7","article-title":"Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients","volume":"186","author":"Schule","year":"2006","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0038|cit38","first-page":"191","article-title":"Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder","volume":"26","author":"Smith","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0039|cit39","unstructured":"Thase ME Kremer C Rodrigues H Mirtazapine versus sertraline after SSRI non-response. 39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14 San Juan; Puerto Rico 2000 260"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0040|cit40","unstructured":"Thase ME Kremer C Rodrigues H Mirtazapine versus sertraline after SSRI nonresponse 52nd Institute on Psychiatric Services; 2000 October 25-29th Philadelphia, PA 2000"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0041|cit41","unstructured":"Thase ME Simmons JH Howland RH Fava M Double-blind, randomized comparison of mirtazapine and sertraline in depressed patients who had not responded to SSRI treatment In preparation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006528.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/S0924-977X(00)80159-5","article-title":"Mirtazapine versus amitriptyline in treatment of major depressive disorder","volume":"10","author":"Turan","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Van Moffaert M Efficacy and safety of mirtazapine vs trazodone in hospitalised depressed patients 8th ECNP (European College of Neuropsychopharmacology) Congress Venice, Italy 1995","DOI":"10.1016\/0924-977X(95)90470-X"},{"issue":"1 Pt B","key":"10.1002\/14651858.CD006528.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002826-199202001-00457","article-title":"Remergon efficacy in major depressive episode: A randomized, double-blind, trazodon-controlled study in 200 Belgian patients","volume":"15","author":"Wilde","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004850-199503000-00001","article-title":"Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression","volume":"10","author":"Moffaert","year":"1995","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00023210-200519020-00004","article-title":"Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients","volume":"19","author":"Versiani","year":"2005","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0047|cit47","first-page":"133","article-title":"A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care","volume":"18","author":"Wade","year":"2003","journal-title":"International Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4088\/JCP.v59n0606","article-title":"Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder","volume":"59","author":"Wheatley","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD006528.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.v64n1013","article-title":"Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia","volume":"64","author":"Winokur","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hup.470100302","article-title":"Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients","volume":"10","author":"Zivkov","year":"1995","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0051|cit51","unstructured":"Blier P Ward HE Jacobs W Herbert C O'Hara SA Pigott TA Combining two antidepressants from treatment start: a preliminary analysis New research program and abstracts, American Psychiatric Association 157th Annual Meeting 2004 157"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0165-0327(00)00296-2","article-title":"Treatment of mood-congruent psychotic depression with imipramine","volume":"66","author":"Bruijn","year":"2001","journal-title":"Journal of Affective Disorders"},{"issue":"12","key":"10.1002\/14651858.CD006528.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4088\/JCP.v59n1203","article-title":"Comparison of 2 treatment strategies for depressed inpatients: Imipramine and lithium addition or mirtazapine and lithium addition","volume":"59","author":"Bruijn","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-2007-979200","article-title":"Depressed in-patients respond differently to imipramine and mirtazapine","volume":"32","author":"Bruijn","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0055|cit55","first-page":"231","article-title":"A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients","volume":"127","author":"Bruijn","year":"1996","journal-title":"Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3956(01)00035-8","article-title":"Trait anxiety and the effect of a single high dose of diazepam in unipolar depression","volume":"35","author":"Bruijn","year":"2001","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1097\/00004714-199704001-00003","article-title":"Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine","volume":"17 Suppl 1","author":"Kasper","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0924-977X(96)00394-X","article-title":"Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline","volume":"7","author":"Kasper","year":"1997","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/S0924-977X(99)80171-0","article-title":"Tolerability of mirtazapine vs SSRIs in short term treatment of major depression","volume":"9","author":"Kremer","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0924-977X(96)87515-8","article-title":"Efficacy of mirtazapine vs clomipramine in severely depressed, hospitalized patients","volume":"6 Suppl 3","author":"Peyron","year":"1996","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00004714-199604000-00006","article-title":"Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine","volume":"16","author":"Tulen","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0062|cit62","first-page":"242","article-title":"Effect of mirtazapine and paroxetine on residual symptoms of depressive disorders and their effect on P450 CYP 2D6 activity","volume":"41","author":"Zourkova","year":"2001","journal-title":"Homeostasis in Health and Disease"},{"issue":"7","key":"10.1002\/14651858.CD006528.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2009.01.015","article-title":"Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation","volume":"19","author":"Blier","year":"2009","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0064|cit64","unstructured":"Catterson ML Preskorn SH Double-blind crossover study of mirtazapine, amitriptyline and placebo in patient with major depression 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9 New York, NY 1996 0157"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0065|cit65","first-page":"55","article-title":"Comparative study of mirtazapine vs clomipramine in treatment of dysthymic disorder","volume":"25","author":"Chang","year":"2006","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0066|cit66","first-page":"100-2, 142","article-title":"Randomized controlled clinical trials of remeron and fluoxetine in depressive patients","volume":"10","author":"Chen","year":"2002","journal-title":"Chinese Journal of Clinical Psychology"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0067|cit67","first-page":"77","article-title":"A study of mirtazapine and venlafaxine in the treatment of depression","volume":"13","author":"Chen","year":"2003","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0068|cit68","first-page":"358","article-title":"Efficacy of mirtazapine and sertraline in the treatment of depression with anxiety symptoms","volume":"18","author":"Chen","year":"2004","journal-title":"Chinese Mental Health Journal"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0069|cit69","first-page":"90","article-title":"Mirtazapine vs. sertraline in treating depressive disorder associated with anxiety","volume":"23","author":"Chen","year":"2004","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0070|cit70","first-page":"25","article-title":"The control study of mirtazapine versus fluoxetine in the treatment of depression","volume":"13","author":"Chen","year":"2005","journal-title":"Chinese Journal of Health Psychology"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/JCP.0b013e3181e7784f","article-title":"Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression: A Double-Blind, Randomized Pilot Study in a Chinese Population","volume":"30","author":"Fang","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0072|cit72","first-page":"154","article-title":"Comparative study on depression treated by citalopram or mirtazapine","volume":"15","author":"Gong","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"7","key":"10.1002\/14651858.CD006528.pub2-BIB0073|cit73","first-page":"489","article-title":"Controlled study of mirtazapine and mianserine in the treatment of senile depression","volume":"19","author":"Guo","year":"2005","journal-title":"Chinese Mental Health Journal"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0074|cit74","first-page":"152","article-title":"Comparison of mirtazapine versus clomipramine in maintenance treatment of depression","volume":"15","author":"Guo","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0075|cit75","first-page":"79","article-title":"Clinical evaluation of mirtazapine and clomipramine for the treatment of depressive disorder associated with anxiety","volume":"6","author":"Guo","year":"2006","journal-title":"Evaluation and Analysis of Drug-Use in Hospitals of China"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0076|cit76","first-page":"413","article-title":"Effect of Mirtazapine and Clomipramine on the Life Quality of Patients","volume":"20","author":"Guo","year":"2006","journal-title":"Chinese Mental Health Journal"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0077|cit77","first-page":"225","article-title":"A comparative study of mirtazapine and paroxetine in the treatment of depression","volume":"18","author":"Hang","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD006528.pub2-BIB0078|cit78","first-page":"885","article-title":"A comparative study of treatment of depression: Mirtazapine vs. fluoxetine","volume":"26","author":"Hu","year":"2004","journal-title":"Zhejiang Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0079|cit79","first-page":"428","article-title":"Comparison of mirtazapine and paroxetine in patients with first-episode climacteric depression","volume":"21","author":"Huang","year":"2007","journal-title":"Chinese Mental Health Journal"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psychres.2008.06.021","article-title":"Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labelled trial","volume":"169","author":"Kang","year":"2009","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1742-1241.2010.02624.x","article-title":"Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: An 8-week open-label randomised paroxetine-controlled trial","volume":"65","author":"Kim","year":"2011","journal-title":"International Journal of Clinical Practice"},{"issue":"9","key":"10.1002\/14651858.CD006528.pub2-BIB0082|cit82","first-page":"637","article-title":"Mirtazapine and fluoxetine in the treatment of cardiovascular neurosis with depression","volume":"19","author":"Li","year":"2005","journal-title":"Chinese Mental Health Journal"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0083|cit83","first-page":"5","article-title":"Comparative study of mirtazapine and sertraline in treatment of elderly depressive patient","volume":"18","author":"Liang","year":"2006","journal-title":"Journal of Heze Medical College"},{"issue":"11","key":"10.1002\/14651858.CD006528.pub2-BIB0084|cit84","first-page":"1229","article-title":"A study of mirtazapine and paroxetine in the treatment of anxiety","volume":"26","author":"Lin","year":"2005","journal-title":"Sichuan Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0085|cit85","first-page":"15","article-title":"A study of mirtazapine and venlafaxine in the treatment of depression","volume":"12","author":"Liu","year":"2004","journal-title":"Health Psychology Journal"},{"issue":"10","key":"10.1002\/14651858.CD006528.pub2-BIB0086|cit86","first-page":"858","article-title":"Comparative study on the efficacy and safety of mirtazapine and amitriptyline in treatment of depression","volume":"12","author":"Ma","year":"2003","journal-title":"Chinese Journal of New Drugs"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0087|cit87","first-page":"63","article-title":"Observation of the clinical efficacy and safety of mirtazapine on elder depression treatment","volume":"13","author":"Ning","year":"2004","journal-title":"Clnical Pharmaceuticals"},{"issue":"12","key":"10.1002\/14651858.CD006528.pub2-BIB0088|cit88","first-page":"853","article-title":"Comparison of efficacy of mirtazapine and fluoxetine in treatment of depression with generalized anxiety disorder","volume":"23","author":"Niu","year":"2004","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"8","key":"10.1002\/14651858.CD006528.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpsychires.2009.11.015","article-title":"Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment","volume":"44","author":"Paslakis","year":"2010","journal-title":"Journal of Psychiatric Research"},{"issue":"11","key":"10.1002\/14651858.CD006528.pub2-BIB0090|cit90","first-page":"664","article-title":"A comparative study of mirtazapine and paroxetine for depressed patients","volume":"16","author":"Peng","year":"2004","journal-title":"Medical Journal of Chinese People Health"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0091|cit91","first-page":"88","article-title":"A study of mirtazapine and paroxetine in the treatment of depression","volume":"14","author":"Ren","year":"2004","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006528.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FPC.0b013e32833b593a","article-title":"ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression","volume":"20","author":"Sarginson","year":"2010","journal-title":"Pharmacogenetics and Genomics"},{"issue":"1-2","key":"10.1002\/14651858.CD006528.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.08.010","article-title":"Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: A randomised open trial","volume":"177","author":"Scharnholz","year":"2010","journal-title":"Psychiatry Research"},{"issue":"12","key":"10.1002\/14651858.CD006528.pub2-BIB0094|cit94","first-page":"1480","article-title":"Comparative study of mirtazapine and paroxetine in the treatment of depression","volume":"21","author":"Su","year":"2005","journal-title":"Modern Medicine and Health"},{"issue":"9","key":"10.1002\/14651858.CD006528.pub2-BIB0095|cit95","first-page":"643","article-title":"Mirtazapine compared with paroxetine in depressed patients with anxiety symptoms","volume":"19","author":"Tang","year":"2005","journal-title":"Chinese Mental Health Journal"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0096|cit96","first-page":"360","article-title":"Clinical efficacy and compliance of mirtazapine in the treatment of depression","volume":"18","author":"Tao","year":"2004","journal-title":"Chinese Mental Health Journal"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0097|cit97","first-page":"24","article-title":"Efficacy and safety of mirtazapine versus clomipramine in patients with depression and anxiety","volume":"18","author":"Wang","year":"2006","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0098|cit98","first-page":"329","article-title":"Mirtazapine vs. fluoxetine in treatment of major depressive disorder: a multicenter clinical trial","volume":"20","author":"Weng","year":"2001","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0099|cit99","first-page":"111","article-title":"Controlled study of mirtazapine vs. venlafaxine in the treatment of depression","volume":"12","author":"Wu","year":"2006","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0100|cit100","first-page":"252","article-title":"Venlafaxine vs buspirone in treating depression associated with anxiety","volume":"10","author":"Xie","year":"2002","journal-title":"Health Psychology Journal"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0101|cit101","first-page":"75","article-title":"A comparative study of mirtazapine and efexor XR for depressive patients","volume":"16","author":"Xie","year":"2004","journal-title":"Medical Journal of Chinese People Health"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0102|cit102","first-page":"32","article-title":"A comparative study of mirtazapine and fluoxetine for depressive patients","volume":"17","author":"Xie","year":"2004","journal-title":"Sichuan Mental Health"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0103|cit103","first-page":"71","article-title":"A comparative study of venlafaxine, maprotiline and buspirone in the treatment of depression","volume":"13","author":"Xie","year":"2005","journal-title":"Chinese Journal of Health Psychology"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0104|cit104","first-page":"93","article-title":"A comparative study of mirtazapine and imipramine for depressive patients","volume":"15","author":"Xiong","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0105|cit105","first-page":"271","article-title":"Clinical comparative study on mirtazapine and venlafaxine used in treating depression","volume":"5","author":"Yang","year":"2005","journal-title":"Nervous Diseases and Mental Health"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0106|cit106","first-page":"202","article-title":"Study of the treatment of depression with mirtazapine, trazodone and maprotiline","volume":"15","author":"Yao","year":"2006","journal-title":"Chinese Journal of Pharmacoepidemiology"},{"issue":"10","key":"10.1002\/14651858.CD006528.pub2-BIB0107|cit107","first-page":"893","article-title":"Mirtazapine in the treatment of depression associated with anxiety","volume":"24","author":"Ye","year":"2005","journal-title":"Herald of Medicine."},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0108|cit108","first-page":"356","article-title":"Mirtazapine and amitriptyline in the maintenance treatment of depressed patients: Comparison of efficacy and compliance","volume":"18","author":"Yu","year":"2004","journal-title":"Chinese Mental Health Journal"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0109|cit109","first-page":"351","article-title":"The control study of mirtazapine versus fluoxetine in the treatment of depression","volume":"15","author":"Zhang","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"30","key":"10.1002\/14651858.CD006528.pub2-BIB0110|cit110","first-page":"4102","article-title":"Control study of mirtazapine and fluoxetine in therapy of depression","volume":"7","author":"Zhang","year":"2003","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0111|cit111","first-page":"184","article-title":"A controlled study of mirtazapine and amitriptyline in depression","volume":"10","author":"Zhang","year":"2004","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0112|cit112","first-page":"440","article-title":"Control study on clinical effect of mirtazapine in treatment depression","volume":"13","author":"Zheng","year":"2005","journal-title":"Chinese Journal of Health Psychology"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0113|cit113","first-page":"355","article-title":"A study of switching to mirtazapine for treatment-resistant depression","volume":"15","author":"Zhu","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0114|cit114","first-page":"277","article-title":"Comparative study of mirtazapine vs. fluoxetine in treatment of elderly depressive patients","volume":"15","author":"Zhu","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0115|cit115","first-page":"546","article-title":"Comparative study of mirtazapine and fluoxetine in the treatment of senile depression","volume":"14","author":"Zhu","year":"2006","journal-title":"China Journal of Health Psychology"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0116|cit116","first-page":"235","article-title":"Comparative study on mirtazapine and paroxetine in the treatment of depression","volume":"16","author":"Zou","year":"2006","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"7","key":"10.1002\/14651858.CD006528.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"issue":"7066","key":"10.1002\/14651858.CD006528.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/026988110001400101","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines","volume":"14","author":"Anderson","year":"2000","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Reviews"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0121|cit121","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0122|cit122","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0123|cit123","article-title":".","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0124|cit124","first-page":"1","article-title":"Practice guideline for the treatment of patients with major depressive disorder (revision)","volume":"157 Suppl","author":"American Psychiatric Association","year":"2000","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1370\/afm.349","article-title":"Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis","volume":"3","author":"Arroll","year":"2005","journal-title":"Annals of Family Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0126|cit126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002791","article-title":"Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)","author":"Barbui","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0127|cit127","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"CMAJ"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1345\/aph.1D267","article-title":"Industry sponsorship and authorship of clinical trials over 20 years","volume":"38","author":"Buchkowsky","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.291.20.2457","article-title":"Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles","volume":"291","author":"Chan","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007852","article-title":"Reboxetine versus other antidepressive agents for depression","author":"Churchill","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004185.pub2","article-title":"Fluoxetine versus other types of pharmacotherapy for depression","author":"Cipriani","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006531","article-title":"Paroxetine versus other anti-depressive agents for depression","author":"Cipriani","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006530","article-title":"Venlafaxine versus other anti-depressive agents for depression","author":"Cipriani","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006117.pub4","article-title":"Sertraline versus other anti-depressive agents for depression","author":"Cipriani","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9665","key":"10.1002\/14651858.CD006528.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006532.pub2","article-title":"Escitalopram versus other antidepressive agents for depression","author":"Cipriani","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD006528.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00228-004-0810-8","article-title":"Are we going to increase the use of antidepressants up to that of benzodiazepines?","volume":"60","author":"Ciuna","year":"2004","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4088\/JCP.v63n0414","article-title":"Prevalence of sexual dysfunction among newer antidepressants","volume":"63","author":"Clayton","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199512004-00004","article-title":"The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission","volume":"10 Suppl 4","author":"Boer","year":"1995","journal-title":"International clinical psychopharmacology"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0141|cit141","first-page":"19","article-title":"The pharmacologic profile of mirtazapine","volume":"57 Suppl 4","author":"Boer","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/j.1440-1614.2004.01377.x","article-title":"Australian and New Zealand clinical practice guidelines for the treatment of depression","volume":"38","author":"Ellis","year":"2004","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0143|cit143","first-page":"123","article-title":"A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety","volume":"59","author":"Fawcett","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jama.297.5.468-b","article-title":"Association between unreported outcomes and effect size estimates in Cochrane meta-analyses","volume":"297","author":"Furukawa","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD006528.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-149-10-200811180-00008","article-title":"Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians","volume":"149","author":"Gartlehner","year":"2008","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0149|cit149","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004186.pub2","article-title":"Amitriptyline versus other types of pharmacotherapy for depression","author":"Guaiana","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4088\/JCP.v66n0612","article-title":"Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000","volume":"66","author":"Guaiana","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0151|cit151","volume-title":"Manual for the ECDEU Assessment Battery.2","author":"Guy","year":"1970"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"415","DOI":"10.7326\/0003-4819-143-6-200509200-00006","article-title":"Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder","volume":"143","author":"Hansen","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0154|cit154","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.170.2.120","article-title":"Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity","volume":"170","author":"Hotopf","year":"1997","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0447.1996.tb10629.x","article-title":"A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients","volume":"93","author":"Hoyberg","year":"1996","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006534","article-title":"Citalopram versus other antidepressive agents for depression","author":"Imperadore","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9546","key":"10.1002\/14651858.CD006528.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(06)69615-3","article-title":"Indirect comparisons: the mesh and mess of clinical trials","volume":"368","author":"Ioannidis","year":"2006","journal-title":"Lancet"},{"issue":"9207","key":"10.1002\/14651858.CD006528.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(99)11381-3","article-title":"SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression","volume":"355","author":"Kent","year":"2000","journal-title":"Lancet"},{"issue":"7400","key":"10.1002\/14651858.CD006528.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"447\u201359","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"Journal of the American Statistical Association"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.1962.01720060019002","article-title":"Clinician's judgments of mental health","volume":"7","author":"Luborsky","year":"1962","journal-title":"Archives of General Psychiatry"},{"issue":"16","key":"10.1002\/14651858.CD006528.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006528.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cct.2004.09.002","article-title":"An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia","volume":"25","author":"Montgomery","year":"2004","journal-title":"Controlled Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/026988119601000310","article-title":"A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression","volume":"10","author":"Mullin","year":"1996","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006529.pub2","article-title":"Milnacipran versus other anti-depressive agents for depression","author":"Nakagawa","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0168|cit168","volume-title":"Depression: management of depression in primary and secondary care","author":"National Institute for Clinical Excellence","year":"2004"},{"issue":"11","key":"10.1002\/14651858.CD006528.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/0895-4356(89)90051-6","article-title":"Issues in the use of change scores in randomized trials","volume":"42","author":"Norman","year":"1989","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006533","article-title":"Duloxetine versus other anti-depressive agents for depression","author":"Nose","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006114.pub2","article-title":"Fluvoxamine versus other anti-depressive agents for depression","author":"Omori","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-116-1-78","article-title":"A consumer's guide to subgroup analyses","volume":"116","author":"Oxman","year":"1992","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006528.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1176\/appi.ajp.162.10.1957","article-title":"Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry","volume":"162","author":"Perlis","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006528.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/070674370404900905","article-title":"Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine","volume":"49","author":"Procyshyn","year":"2004","journal-title":"Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00004850-199703000-00005","article-title":"Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability","volume":"12","author":"Puech","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v62n0509","article-title":"Does mirtazapine have a more rapid onset than SSRIs?","volume":"62","author":"Quitkin","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0177|cit177","unstructured":"Ramsay C Gates S Unit of analysis issues UK Contributors meeting Manchester The Cochrane Collaboration 2005"},{"issue":"2","key":"10.1002\/14651858.CD006528.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1176\/ajp.2007.164.2.201","article-title":"STAR*D: what have we learned?","volume":"164","author":"Rush","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006528.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Statistical Methods in Medical Research"},{"issue":"5","key":"10.1002\/14651858.CD006528.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00019442-200209000-00007","article-title":"Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients","volume":"10","author":"Schatzberg","year":"2002","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1192\/bjp.180.5.396","article-title":"Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis","volume":"180","author":"Smith","year":"2002","journal-title":"British Journal of Psychiatry"},{"issue":"7387","key":"10.1002\/14651858.CD006528.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1520-6394(1997)6:1<10::AID-DA2>3.0.CO;2-9","article-title":"Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis","volume":"6","author":"Steffens","year":"1997","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0185|cit185","unstructured":"Thase ME Baker R Simmons J van Willigenburg AP Heukels AJ Janssens CJ More rapid onset of effect on the core symptoms of depression with mirtazapine than SSRIs American Psychiatric Association 2005 Annual Meeting Atlanta 2005"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0186|cit186","first-page":"S83","article-title":"Effect of mirtazapine versus SSRIs on core symptoms of depression","volume":"91 Suppl 1","author":"Thase","year":"2006","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"10.1002\/14651858.CD006528.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/YIC.0b013e328330adb2","article-title":"Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression","volume":"25","author":"Thase","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0189|cit189","volume-title":"SF-36 Health Survey Manual and Interpretation Guide","author":"Ware","year":"1993"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0190|cit190","volume-title":"The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0191|cit191","article-title":"Revised Global Burden of Disease 2002 estimates","volume-title":"http:\/\/www.who.int\/healthinfo\/bodgbd2002\/en\/index","author":"World Health Organization","year":"2006"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0192|cit192","unstructured":"World Health Organization WHO Collaborative Centre for Drug Statistics Methodology http:\/\/www.whocc.no\/atcddd\/ 2006"},{"issue":"12","key":"10.1002\/14651858.CD006528.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0277-9536(98)00009-4","article-title":"The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties","volume":"46","author":"WHOQOL Group","year":"1998","journal-title":"Social Science and Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0895-4356(02)00537-1","article-title":"Comparative responsiveness of generic and specific quality-of-life instruments","volume":"56","author":"Wiebe","year":"2003","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD006528.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"743","DOI":"10.7326\/0003-4819-132-9-200005020-00011","article-title":"A systematic review of newer pharmacotherapies for depression in adults: evidence report summary","volume":"132","author":"Williams","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"II6","DOI":"10.1007\/BF03035120","article-title":"Standardizing the Hamilton Depression Rating Scale: past, present, and future","volume":"251 Suppl 2","author":"Williams","year":"2001","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD006528.pub2-BIB0197|cit197","volume-title":"Measuring mental health outcomes: a perspective from the Royal College of Psychiatrists. Outcomes into Clinical Practice","author":"Wing","year":"1994"},{"issue":"9","key":"10.1002\/14651858.CD006528.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4088\/JCP.v69n0908","article-title":"Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis","volume":"69","author":"Watanabe","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006528.pub2-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/11319480-000000000-00000","article-title":"Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis","volume":"24","author":"Watanabe","year":"2010","journal-title":"CNS Drugs"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006528.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:04:24Z","timestamp":1787529864000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006528.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,7]]},"references-count":199,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006528.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,7]]}}}